Proliferative potential in benign mixed salivary gland tumors, using Ki67 marker in relation to different clinicopathological parameters
AbstractBackground and objective: Pleomorphic adenoma is the most common benign tumor of the salivary gland. It shows a remarkable degree of morphological diversity. Immunohistochemical Ki67 expression is used to predict the proliferative potential of the growth. The aim of this study was to evaluate the expression of the proliferation marker Ki-67 in benign mixed salivary gland tumors. Methods: Fifty five paraffin embedded tissue blocks were included in the study. After histopathological reassessment of hematoxylin and eosin stained section for each block, an immunohistochemical staining was performed using anti-Ki67 protein. Results: From total number of 55 cases, 58.1% of patients were in group aged ≤ 40 years. The male to female ratio was 1.037:1. The parotid gland was the most affected (56.37%) gland. The mean duration of lesions before treatment was 17.96 months and the mean size of tumors was 3.76 cm. Histologically, cell-rich subtype constituted 54.54%, followed by stroma-rich (34.55%), and only 10.91% of cases were classic. Ki67 expression was positive in 18.18% predominantly in epithelial variant with a weak score in nine cases (16.36%). Six of positive cases were in parotid gland and two cases in the submandibular gland. Only one case was in minor salivary gland. Moderate Ki67 expression score was seen in one epithelial variant case (14.28 %) associated with parotid gland. Conclusion: Immunohistochemical expression of Ki-67 in pleomorphic adenoma was characterized by low proliferative rate and predominantly seen in epithelial tumor variants.
Atarbashi S, Elahi M, Khani M, Rakhshan. Immunohistochemical analysis of B-cell lymphoma-2 in pleomorphic adenoma and mucoepidermoid carcinoma. Dent Res J; 2014.11(2): 257–63
Neville BW, Damm DD, Allen CM, Bouquet JE .Oral and Maxillofacial Pathology. 2nded, Philadelphia: W.B. Saunders; 2002.P. 373- 88.
Mendenhall WM, Mendenhall CM, Werning JW, Malyapa RS, Mendenhall NP. Salivary gland pleomorphic adenoma. Am J Clin Oncol 2008; 31:95-9
Alves FA, Perez DE, Almeida OP, Lopes MA, Kowalski LP. Pleomorphic adenoma of the submandibular gland: clinicopathological and immunohistochemical features of 60 cases in Brazil. Arch Otolaryngol. Head Neck Surg 2002; 128:1400 – 7.
Marioni G, Marino F, Stramare R, Marchese-Ragona R, Staffieri A. Benign metastasizing pleomorphic adenoma of the parotid gland: a clinicopathologic puzzle. Head Neck 2003; 25:1071-6.
Yasmyne S. The mechanism of malignant transformation in benign salivary gland tumors. MSc thesis in Biology, University of Toledo; 2009.
David W, David S, Ray L, Andrew JEC Text book of general and oral surgery.3rd ed. London: Churchill Livingstone; 2003. P. 274.
Eveson J, Kusafuka K, Stenman G, Nagao T. Tumors of the salivary glands. In: Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and Genetics of Head and Neck Tumors. Lyon, France: IARC Press 2007.P. 254-8.
Cawson RA, Odell EW. Cawson’s essential oral pathology and Oral Medicine. 7th ed. Churchill Livingstone 2002; 255 – 74.
Rassol H J, Al Soudani K. Immunohistochemical expression of D2-40, VEGF and PCNA as biological markers of lymphangiogenisis, angiogenesis and proliferation in pleomorphic adenoma of salivary gland origin J Bagh college Dentistry 2013 ; 25 (1): 53-8
Triantafillidou K, Dimitrakopoulos J, Iordanidis F, Koufogiannis D. Mucoepidermoid carcinoma of minor salivary glands: A clinical study of 16 cases and review of the literature. Oral Dis 2006; 12:364-707.
Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182:311-22.
Gimotty PA, Belle P, Elder DE, Murry T, Montone KT, Xu X. Biologic and Prognostic Significance of Dermal Ki67 Expression, Mitoses, and Tumorigenicity in Thin Invasive Cutaneous Melanoma. J Clin Oncol 2005; 23:8048-56.
Alves FA, Piers FR, de Almeida OP, Lopes MA, Kowalski LP. PCNA, Ki-67 and p53 expressions in submandibular salivary gland tumors. J Oral Maxillofac Surg 2004; 33:593-7.
Lazzaro B, Cleveland D.p53andKi-67antigen expression in small oralBiopsy specimens of salivary gland tumours. Oral Surg Oral Med Oral Pathol Oral Radiol 2000; 89:613-7.
Dean AG, Sullivan KM, Soe MM. OpenEpi: Open source epidemiologic statistics for public health,
Version 3.03. www.OpenEpi.com, updated 2014/09/22, accessed 2014/11/26.
Rasheed S, Majeed A. Immunohistochemical Expression of Actin and S100 in pleomorphic adenoma and Mucoepidermoid carcinoma. J Bagh College Dentistry 2011; 23(2): 51-5.
Al-Ani LS, Al-Azzawi LM, Evaluation of Immunohistochemical Expression of P53 and Pcna in Pleomorphic Adenoma, Mucoepidermoid and Adenoid Cystic Carcinomas of Salivary Glands. Tikrit Journal for Dental Sciences 2014; 3(1):1-8.
Chau MN, Radden BG: A clinical-pathological study of 53 intra-oral pleomorphic adenomas. Int J Oral Maxillofac Surg 1989; 18(3):158-62.
Ohtake S, Chen J, Ida H, Suzuki M, Ohshiro K, Zhang W. Precancerous foci in pleomorphic adenoma of salivary gland: Recognition of focal carcinoma and atypical tumor cells by p53 immunohistochemistry. Oral Pathol Med 2002; 3:590-7.
Margaritesscu CL, Raica M, Simionescu C, Mogoanta L, Surpateanu M, Jaubert F, et al. Tumoral stroma of salivary pleomorphic adenoma –histopathological, histochemical and immunohistochemical study. Rom J Morphol Embryol2005; 46(3):211– 3.
Ito F, Jorge J, Vargas P, Lopes M. Histopathological findings of pleomorphic adenomas of the salivary glands. Med Oral Patol Oral Cir Bucal 2009; 14 (2):E57-61.
Anna Kazanceva, Alerie Groma, Lieneman, Egil Kornevs, Uldis Teibe. Proliferative potential in benign mixed salivary gland tumors, St anditsvaluein primaryand recurrent neoplasm Stomatologija Baltic Dental and Maxillofacial Journal 2011; 13:35-41.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).